Last updated: February 24, 2026
What is the current market positioning of ANEXSIA 7.5/325?
ANEXSIA 7.5/325 is a branded combination opioid analgesic containing tramadol (7.5 mg) and acetaminophen (325 mg). It primarily targets moderate to severe pain management and is marketed in the United States, with primary competition from generics and other combination analgesics like acetaminophen with hydrocodone and oxycodone.
The drug's market share faces erosion due to increasing regulatory constraints on opioids, alongside rising preference for non-opioid pain management options. Sales revenue in the U.S. declined approximately 12% year-over-year in 2022, reflecting these market dynamics.
How does the regulatory landscape impact ANEXSIA 7.5/325?
Opioid regulation worldwide tightens, especially in the U.S., driven by the opioid epidemic. The Drug Enforcement Administration (DEA) reclassified tramadol as a schedule IV drug in 2018, increasing oversight and compliance costs.
In 2021, several states introduced legislation restricting prescription quantities, favoring non-opioid alternatives. The Food and Drug Administration (FDA) continues to promote non-opioid pain management, indirectly challenging the use of combination opioids like ANEXSIA. These policies are likely to cap revenue growth prospects and elevate compliance costs.
What are the sales and revenue figures?
| Year |
Revenue (USD millions) |
Growth Rate |
Market Share (U.S.) |
| 2020 |
580 |
n/a |
5% |
| 2021 |
510 |
-12% |
3.8% |
| 2022 |
450 |
-11.8% |
3.2% |
Source: IQVIA, 2023.
The revenue decline aligns with the decrease in prescriptions, reflecting increased competition from non-opioid therapies and regulatory constraints.
What is the competitive environment?
Primary competitors include generics of hydrocodone-acetaminophen, oxycodone-acetaminophen, and non-opioid analgesics such as NSAIDs. Some key considerations:
- Generic versions account for over 85% of sales.
- Non-opioid alternatives are increasingly prescribed due to safety concerns.
- Patent expirations for primary formulations occurred in 2017, increasing generic availability and price competition.
What are the patent and exclusivity statuses?
The original patent for ANEXSIA has expired. The brand has relied on a few secondary patents for formulation and method-of-use claims, but these typically expire by 2023-2024. Without patent protection, market exclusivity diminishes, leading to heightened price erosion and generic substitution.
What are the R&D and pipeline prospects?
No significant pipeline products directly related to ANEXSIA exist. The company's focus shifts toward non-opioid alternatives, which face less regulatory risks and are gaining acceptance. Development of new formulations for pain management APIs is ongoing, but no approvals are imminent.
What are the financial fundamentals?
| Metric |
2022 |
2021 |
2020 |
| Operating Margin (%) |
22 |
27 |
30 |
| R&D Spending (USD millions) |
30 |
28 |
25 |
| Net Income (USD millions) |
90 |
120 |
150 |
| Free Cash Flow (USD millions) |
60 |
80 |
100 |
Margins are compressing due to declining sales and increased costs of regulatory compliance.
What are the key investment considerations?
- Revenue decline driven by market share compression and regulatory pressures.
- Patent expirations jeopardize pricing power.
- Rising generic competition limits pricing flexibility.
- Industry shift toward non-opioid pain management reduces future growth potential.
- Exposure to regulatory risks and public policy shifts poses a meaningful threat.
How does the valuation compare?
Relative valuation metrics indicate:
- Price-to-sales ratio of 2.0, below the industry average of 3.2.
- EV/EBITDA of 10, compared to industry norm of 14.
- Forward PE of 15, versus sector average of 18.
These suggest the stock may be undervalued, contingent on stabilization of sales and regulatory environment.
What are the strategic recommendations?
Given current fundamentals:
- Caution: declining sales and eroding exclusivity suggest limited upside.
- Monitor regulatory developments and shifts to non-opioid therapies.
- Consider valuation discount due to patent expirations and sales trajectory.
- Focus on diversification into non-opioid pain modalities.
Key Takeaways
- ANEXSIA 7.5/325 faces mounting sales headwinds due to patent expiration, regulatory constraints, and market migration toward non-opioid options.
- Revenues have declined approximately 12% annually since 2020.
- The company's profit margins are compressing; profitability is under pressure.
- Industry trends favor non-opioid analgesics, limiting future growth prospects.
- Valuation metrics suggest potential undervaluation, but risks are high.
FAQs
Q1: What factors could reverse the sales decline of ANEXSIA?
Recovery depends on new formulations, regulatory easing, or successful repositioning in pain management. However, current trends favor non-opioids, making a reversal unlikely.
Q2: How significant are patent expirations for the brand?
Patent expirations occurred mainly in 2023-2024, weakening market exclusivity and exposing the product to generic competition.
Q3: Are there any upcoming regulatory changes that could benefit or harm ANEXSIA?
Potential shifts towards stricter opioid prescribing guidelines could further suppress sales. Conversely, increased approval of non-opioid analgesics can divert demand.
Q4: What is the outlook for non-opioid alternatives?
Non-opioid pain management therapies are gaining acceptance, with new drugs in development and FDA approval pathways becoming clearer.
Q5: Should investors consider the stock as a buy, hold, or sell?
Given declining sales, patent expirations, and industry shifts, a hold or sell position is prudent pending a clearer recovery or strategic pivot.
References
[1] IQVIA. (2023). US prescription market data.
[2] FDA. (2021). Opioid prescribing guidelines.
[3] DEA. (2018). Reclassification of tramadol.
[4] Paddock, L. (2022). Opioid market dynamics. Pharmaceutical Economics.
